

Board transition and key personnel appointments

23 September 2026

Highlights

- Professor Christine Jenkins AM, one of Australia's most influential figures in respiratory medicine, appointed as an independent Non-Executive Director
- Chair, Lil Bianchi, will not stand for re-election and will retire from the Board at the conclusion of the 2026 AGM
- Julian Sutton, current Chief Financial Officer and Executive Director, has been appointed Executive Chair, effective immediately following the 2026 AGM
- Chris Cox, Financial Controller and former Interim CFO, promoted to Chief Financial Officer, effective at the close of the 2026 AGM
- Beth Plunkett, Head of Legal, promoted to General Counsel

Melbourne, Australia, 23 September 2026: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, today announces a planned Board transition and key personnel appointments to support its next phase of commercial growth.

Current Chair, Lil Bianchi, has confirmed that she will not stand for re-election as a Non-Executive Director at the Company's upcoming Annual General Meeting (AGM). The Company announces the appointment of Professor Christine Jenkins AM as an independent Non-Executive Director, and the appointment of Julian Sutton, currently Chief Financial Officer and Executive Director, as Executive Chair effective immediately following the AGM. The Company also announces the promotion of Chris Cox to Chief Financial Officer and Beth Plunkett to General Counsel.

Lil Bianchi retires from the Board

4DMedical MD/CEO and Founder Andreas Fouras said:

On behalf of the Board and the entire 4DMedical team, I would like to thank Lil for her contribution over the past seven years. During her tenure, Lil has provided thoughtful guidance and strong governance through an important period in the Company's development. Her contribution as Chair over the past three years has been particularly valuable as 4DMedical has transitioned from a technology-focused company into a global medical imaging business with an expanding commercial footprint. We are grateful for Lil's commitment and support, and wish her every success for the future.

Lil Bianchi commented:

It has been my privilege to serve on the 4DMedical Board and chair the Company through a transformational period. The Company is well positioned for the next phase, and I have decided this AGM is the right time to hand over. CT:VQ® is cleared, approved or certified in the world's major markets and commercial adoption is building across the US and internationally. The Company has globally unique technology, a strong Board and an outstanding management team, and I look forward to 4DMedical's on-going success.



Professor Christine Jenkins AM appointed to the Board

Professor Jenkins is one of Australia's most influential figures in respiratory medicine. Over a distinguished career spanning four decades, she has combined clinical practice, research, education and policy leadership at the highest levels of the profession. She served as a senior staff specialist in respiratory medicine at Concord Hospital for 40 years, has led more than 34 clinical trials as principal investigator and authored more than 320 publications.

Her work has focused on improving diagnostic pathways and outcomes for patients with respiratory disease, particularly those presenting with breathlessness, COPD and asthma. She currently leads a Medical Research Future Fund trial developing a digital tool to assist general practitioners in assessing and managing patients with breathlessness.

Professor Jenkins has held many of the most senior leadership positions in Australian respiratory medicine, including Chair of Lung Foundation Australia, the Thoracic Society of Australia and New Zealand and the National Asthma Council. She has also played a central role in shaping national respiratory health policy, clinical standards and patient advocacy initiatives.

She was appointed a Member of the Order of Australia for services to respiratory medicine as a clinician, administrator and educator. She is a Fellow of both the Thoracic Society of Australia and New Zealand and the Australian Academy of Health and Medical Sciences.

Andreas Fouras commented:

Christine is one of the most respected figures in Australian respiratory medicine, and her appointment strengthens the Board at exactly the right moment. We have spent a decade proving that lung function can be measured in ways that were not previously possible. The task now is adoption, and adoption is won through clinical leadership, inclusion in guidelines and care pathways, and a compelling evidence base. Christine has spent her career in all three. Her research on efficient diagnostic pathways for patients presenting with breathlessness, and on the interaction between cardiac and respiratory disease, is precisely the clinical problem CT:VQ® was built to address.

Christine also brings a national perspective on lung health policy, having chaired Lung Foundation Australia, the Thoracic Society of Australia and New Zealand and the National Asthma Council. As we expand in Australia alongside our US and European markets, that voice on the Board matters. Together with Geraldine McGinty and Robert Figlin, Christine gives 4DMedical a Board with genuine depth in clinical practice, imaging and health policy. I am delighted to welcome her.

Christine Jenkins commented:

Functional lung imaging has the potential to change how we diagnose and manage respiratory disease. Throughout my career I have seen patients with breathlessness wait too long for a clear diagnosis, often moving between specialists and tests before the cause is understood. The ability to see regional ventilation and perfusion together speaks directly to questions I have worked on for many years, including how we assess breathlessness efficiently and how cardiac and respiratory disease interact in patients with COPD.

New technology only makes a difference to patients when clinicians trust it, the evidence supports it and it fits within the way care is delivered. I look forward to working with the Board and management to help 4DMedical bring its technology into routine clinical practice, in Australia and internationally.



Julian Sutton appointed Executive Chair

The Board has appointed Julian Sutton as Executive Chair, effective immediately following the 2026 AGM. Julian is an early investor in 4DMedical and served as a Non-Executive Director from September 2017 before being appointed Chief Financial Officer and Executive Director in January 2026.

As CFO, Julian has been central to strengthening the Company's balance sheet, leading the capital raisings completed during FY26 that funded the commercial rollout of CT:VQ[®] and established a year-end cash position of \$278 million.

In addition to capital strategy and investor relations, Julian has led the Company's corporate development activity, including the acquisition of contextflow, and has worked closely with the executive team on corporate governance and commercial operations across nine years as a director.

As Executive Chair, Julian will retain executive responsibility for the Company's finance, legal and capital markets activities, working alongside Dr Fouras, who continues to lead the Company as Managing Director and CEO.

Julian will continue to be employed on the terms disclosed in the Company's ASX announcement of 2 January 2026, which remain unchanged in connection with his appointment as Executive Chair. No new or amended terms apply.

Andreas Fouras said:

Julian has been central to 4DMedical for nine years, first as an investor and director and most recently as CFO. He led the capital raisings that have taken us from a company managing its runway to one with the balance sheet to fund a global commercial rollout, and he has done that while keeping dilution tightly controlled and bringing high-quality global institutions onto our register.

As Chair, Julian brings a rare combination of deep knowledge of the technology, the capital markets experience the next phase demands, and a long working relationship with the entire management team. I look forward to continuing to work alongside him as we scale.

Julian Sutton said:

I have backed 4DMedical since 2017 because I believe this technology will change respiratory medicine. That conviction is stronger now than it has ever been, with CT:VQ[®] cleared for use in our major markets, adoption building at leading institutions, and a balance sheet that can fund the opportunity ahead.

I want to thank Lil for her leadership and for the Board she leaves behind. My focus as Chair will be on supporting Andreas and the executive team to convert regulatory approval and clinical interest into sustained commercial adoption, and on the disciplined allocation of capital in the interests of shareholders.

Board Composition

Following the 2026 AGM, the Board will comprise Julian Sutton (Executive Chair), Dr Andreas Fouras (Managing Director and CEO), John Livingston, Dr Robert Figlin, Dr Geraldine McGinty and Professor Christine Jenkins AM.

Chris Cox appointed Chief Financial Officer

The Company is pleased to announce the appointment of Chris Cox to the role of CFO, effective following the close of the 2026 AGM. Chris joined 4DMedical as Financial Controller in August 2023, also serving as 4DMedical's Interim CFO from March 2025 to December 2025. Chris led the finance function through



multiple acquisitions and capital raisings and has played a central role in building the financial capability required to support the Company's continued expansion.

Prior to joining 4DMedical, Chris held finance leadership roles at healthcare companies Invetech and MedAdvisor Limited. Chris is a member of Chartered Accountants Australia and New Zealand and holds a Bachelor of Commerce (Accounting/Finance).

Andreas Fouras said:

Chris has been at the centre of 4DMedical's finance function for three years, through the Imbio and contextflow acquisitions, multiple capital raisings and our transition to a global commercial business. He held the CFO role on an interim basis through 2025 and has the confidence of the Board and the executive team.

This is a natural and well-planned succession. Chris knows the business, the systems and the discipline required to scale a company through commercialisation, and I am pleased to confirm him in the role.

Beth Plunkett appointed General Counsel

4DMedical is pleased to announce the appointment of Beth Plunkett as General Counsel, effective immediately. Beth joined 4DMedical as Legal Counsel in April 2021 before being promoted to Head of Legal in October 2025. During her time with the Company, Beth has played a key role in supporting 4DMedical's growth and strategic initiatives across commercial, corporate and governance matters, including acquisitions, international expansion activities, licensing and strategic collaboration arrangements.

Prior to joining 4DMedical, Beth spent more than seven years with Smile Solutions, one of Australia's largest private dental groups. Beth is a legal practitioner and holds a Juris Doctor from the University of Melbourne.

As General Counsel, she will continue to lead 4DMedical's global legal function and work closely with the Board and executive team as the Company scales its commercial operations in the United States, Australia and other markets.

Andreas Fouras said:

Beth has been an outstanding contributor to 4DMedical's growth over the past five years. Her appointment as General Counsel reflects both the quality of her work and the increasing scale and complexity of our business. We congratulate Beth and look forward to her continued leadership.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS**®), **CT LVAS**™, and the ground-breaking **CT:VQ**® solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio** and 2026 acquisition of **contextflow**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com